BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

bioRASI to Present at the MAGI 2009 Clinical Research Conference in Miami, FL


5/27/2009 9:27:16 AM

HOLLYWOOD, FL--(Marketwire - May 27, 2009) - bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will be participating in the MAGI 2009 Clinical Research Conference on May 31st - June 3rd. Dr. Boris Reznik, Chairman of bioRASI, will be a keynote speaker at the event's symposium titled, "Lessons Learned, Study Post Mortems." Leading the Symposium, Dr. Reznik will be discussing the issues of improving Clinical Research Processes through applying Deming's "Continues Improvement Process" (CIP).

"Too often, 'Lessons Learned' is reduced to trying to derive value from anecdotal review of the issues after the clinical trials are completed," Dr. Boris Reznik said. "At bioRASI, in order to consistently increase the quality of our work, we have been applying a method developed by the legendary W. Edwards Deming: 'Continues Improvement Process.' We not only believe that our approach produces significantly improved results, but we actually can measure them. The successful implementation of CIP at bioRASI was based upon making CIP a part of bioRASI's standard operating infrastructure: BPI 2008."

Through its Innovative and Generics divisions, bioRASI leverages its in-depth knowledge and global resources to provide a full range of services to its sponsors, including program management, regulatory strategy design and implementation, clinical development, analytical lab services, Part 11 compliant data management, data analysis and report writing.

bioRASI has leveraged its unique global access to strong PIs and special patient populations to optimize translational clinical development programs. Additionally, utilizing bioRASI's Phase I clinics and bioanalytical laboratories, bioRASI has a rich history of completing difficult to recruit and difficult to perform PK, BE and BA studies.

About bioRASI

bioRASI is a Full Service Global CRO that collaborates with the leading biotech and pharmaceutical companies in the clinical development of novel and generic therapeutics. Specializing in Innovative, ANDA and 505(b)(2) NDA programs, bioRASI facilitates obtaining FDA approvals by delivering high quality regulatory and clinical strategies, solutions and services, while saving their clients critical time. bioRASI services include program management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI leverages its access to world renowned researchers and facilities in the U.S., Europe and Asia, to achieve unparalleled scientific, clinical and business results at significantly lower costs. bioRASI is headquartered in Hollywood, FL and has regional offices, labs, and clinics across the globe.


Contact:
Lindsey Hall
(786) 388-0700
Email Contact
www.biorasi.com



Read at BioSpace.com

bioRASI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES